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Background: Presently, there is no effective treatment for the lethal muscle wasting disease Duchenne muscular
dystrophy (DMD). Here we show that increased sphingosine-1-phoshate (S1P) through direct injection or via the
administration of the small molecule 2-acetyl-4(5)-tetrahydroxybutyl imidazole (THI), an S1P lyase inhibitor, has
beneficial effects in acutely injured dystrophic muscles of mdx mice.
Methods: We treated mdx mice with and without acute injury and characterized the histopathological and
functional effects of increasing S1P levels. We also tested exogenous and direct administration of S1P on mdx
muscles to examine the molecular pathways under which S1P promotes regeneration in dystrophic muscles.
Results: Short-term treatment with THI significantly increased muscle fiber size and extensor digitorum longus
(EDL) muscle specific force in acutely injured mdx limb muscles. In addition, the accumulation of fibrosis and fat
deposition, hallmarks of DMD pathology and impaired muscle regeneration, were lower in the injured muscles of
THI-treated mdx mice. Furthermore, increased muscle force was observed in uninjured EDL muscles with a longer-
term treatment of THI. Such regenerative effects were linked to the response of myogenic cells, since intramuscular
injection of S1P increased the number of Myf5nlacz/+ positive myogenic cells and newly regenerated myofibers in
injured mdx muscles. Intramuscular injection of biotinylated-S1P localized to muscle fibers, including newly
regenerated fibers, which also stained positive for S1P receptor 1 (S1PR1). Importantly, plasma membrane and
perinuclear localization of phosphorylated S1PR1 was observed in regenerating muscle fibers of mdx muscles.
Intramuscular increases of S1P levels, S1PR1 and phosphorylated ribosomal protein S6 (P-rpS6), and elevated EDL
muscle specific force, suggest S1P promoted the upregulation of anabolic pathways that mediate skeletal muscle
mass and function.
Conclusions: These data show that S1P is beneficial for muscle regeneration and functional gain in dystrophic
mice, and that THI, or other pharmacological agents that raise S1P levels systemically, may be developed into an
effective treatment for improving muscle function and reducing the pathology of DMD.Background
Duchenne muscular dystrophy (DMD) is a muscle wast-
ing disease for which there is no cure. This severe X-
linked recessive disease affects 1 in 3,500 male births
[1]. In dystrophic muscles, rounds of contractions result
in degeneration/regeneration cycles. In turn, dystrophic
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Since no effective treatment presently exists and the im-
mune response to dystrophin has hampered gene ther-
apy approaches, new advances for the treatment of
DMD are imperative [2,3].
Previously, sphingosine-1-phosphate (S1P) has been im-
plicated in muscle repair, satellite cell proliferation, myo-
blast differentiation in vitro and in non-diseased mouse
models in vivo [2,4-6]. These essential roles for S1P in
skeletal muscle regeneration suggested that elevation of
S1P may have therapeutically beneficial effects in models
of disease [7]. More recently, S1P has been shown benefi-
cial for activating satellite cells in dystrophic muscles [8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Drosophila revealed that by increasing S1P levels via re-
duction of the lipid phosphate phosphatase 3 (LPP3)
homolog, wunen, or the S1P lyase, sply, prevents to a large
degree dystrophic muscle wasting in flies [9]. In mice,
elevation of S1P by the genetic reduction of S1P lyase
can be phenocopied pharmacologically via treatment
with the small molecule 2-acetyl-4(5)-tetrahydroxybutyl
imidazole (THI) [10,11]. Furthermore, in Drosophila,
THI treatment also significantly suppresses the dys-
trophic muscle phenotype [9].
Utilizing the mdx mouse model, we initiated studies
on the effect of increasing S1P levels in dystrophic mice,
and found that short-term treatment with THI improves
muscle integrity and function following acute injury with
cardiotoxin (CTX). THI treatment also leads to signi-
ficant improvements of the pathology of dystrophic
muscles, as indicated by the reduced accumulation of fi-
brosis and fat deposition in acutely injured muscles. In
turn, intramuscular injection of S1P resulted in an in-
creased number of myogenic cells and newly regenerat-
ing fibers in vivo. S1P receptor 1 (S1PR1) is expressed by
many muscle cell types, particularly muscle fibers, and
phosphorylated S1PR1 is localized in the plasma mem-
brane and intracellularly (perinuclear localization) of
muscle fibers. Intramuscular S1P administration results
in increased levels of total and phosphorylated S1PR1
and ribosomal protein S6 (rpS6). This suggests that in-
creases in fiber size are mediated by anabolic pathways
that promote greater skeletal muscle mass and function,
potentially through S1PR1 signaling. Furthermore, ex vivo
administration of S1P improved specific force in uninjured
dystrophic muscle. Similarly, longer-term THI treatment
of uninjured young mdx mice resulted in increased exten-
sor digitorum longus (EDL) muscle force in the absence of
CTX injury. Altogether, S1P acts at multiple levels in mus-
cles, particularly in myogenic cells and muscle fibers, and
collectively the actions of S1P in muscle are beneficial for
regeneration in the setting of muscular dystrophy.
Methods
Animal procedure
Experiments involving animals were undertaken in ac-
cordance with approved guidelines and ethical approval
from the Institutional Animal Care and Use Committee,
University of Washington, Seattle, WA, USA.
THI injections in injured mice
Peripheral blood cells from 1.5-month-old (MO) wild
type (wt) C57BL/k6 and mdx mice on a C57BL/k6 back-
ground (B6Ros.Cg-Dmdmdx-4Cv/J, herein referred to as
mdx4cv) were analyzed (Figure 1A). Blood was collected
before and 12 hours following the last of two 250 μl in-
traperitoneal (IP) injections of 0.15 mg/ml THI in PBS.Injections were 6 hours apart. This injection regimen and
dose was repeated for all subsequent experiments involv-
ing THI, but for longer-treatment durations as outlined.
Six 5-MO mdx4cv males were used for the experiments in
Figure 1B, and Additional file 1: Figure S1 and S2. For
Figures 2 and 3, and Additional file 1: Figures S3 to S7, six
11-MO females and seven 16-MO males mdx4cv were
used for these experiments. In these mice, the left tibialis
anterior (TA) and quadriceps femoris (quads) were injured
with 10 nM CTX (Calbiochem, Darmstadt, Germany)
from Naja nigricollis. Once more, THI-treated mice were
injected IP with 250 μl 0.15 mg/ml THI in PBS, twice daily
(injections 6 hours apart) immediately after injury and for
the first 3 days following injury. The vehicle controls were
injected IP with PBS. On day 4 post injury, 5-MO mdx4cv
animals were euthanized for S1P and creatine kinase (CK)
analysis. On day 17 post CTX, 11-MO and 16-MO mdx4cv
mice were also injected IP with 1% Evans Blue dye (EBD)
to label persistently damaged (dye permeable) muscle fi-
bers [12], and euthanized on day 18 post injury for his-
topathology analysis. Muscles for S1P and expression
analysis (from 5-MO mdx4cv) were frozen directly in liquid
nitrogen, while muscles taken for histopathology were fro-
zen under liquid nitrogen cooled isopentane in optimal
cutting temperature (OCT) compound. All myofibers
were measured for the minimum diameters on the cross-
sections of mouse quadriceps muscle using ImageJ software
(Bethesda, MD, USA). Between 750 and 850 myofibers
were counted for three mice treated with PBS or THI,
with or without CTX injury. For functional analysis
outlined in Figure 4B, 4.75- to 5-MO male mdx on a
C57BL/10 background (C57BL/10ScSn-Dmdmdx/J) were
used for the 14-day treatment of THI or vehicle. Following
the same dose and treatment regimen, mdx were treated
with THI (n = 10) or vehicle (n = 9) for 14 days following
CTX injury to left TAs and quadriceps. The same mdx
strain was compared to wt C57BL/10 animals in Figure 4C
and for exogenous S1P treatment depicted in Figure 4D.
Animals used to evaluate the degree of CTX injury in EDL
(Additional file 1: Figure S8) were 4-MO female mdx
(n = 4, C57BL/10ScSn-Dmdmdx/J background), injected in
left TAs with CTX and with approximately 3 μl India ink,
added to the tip of the needle to mark injection penetra-
tion. Following CTX injections, mice were immediately
injected IP with 1% EBD. Both left (injured) and contralat-
eral uninjured TA and EDL muscles were harvested and
frozen in OCT compound 12 hours post injury.
THI treatment in drinking water of young, uninjured mdx
mice
Beginning at 4 weeks of age, male mdx4cv were treated
with THI (n = 4) or vehicle (n = 3) for 4 weeks, and ana-
lyzed by EDL myography at 8 weeks of age. For this
treatment we followed the dose and conditions described
Figure 1 IP injection of THI reduces peripheral blood leukocytes and increases S1P levels in most tissues. (A) Leukocytes were analyzed
from the peripheral blood of 1.5-MO mdx4cv mice (n = 3) before and 12 hours following treatment with THI (2 × 250 μl 0.15 mg/ml IP injections,
6 hours apart). IP administration of THI significantly reduced circulating leukocytes to values below or near age-matched wt (n = 4). The average
value of each population is listed in the table below the bar graph. Values between pre and post THI, and wt were also significant by ANOVA
(P <0.05) for all leukocytes except monocytes. (B) mdx4cv mice (n = 6, 5-MO) were treated with THI or vehicle for 3 days (2 × 250 μl 0.15 mg/ml
IP injections per day) following CTX injury to assess changes in S1P muscle content. Muscles and spleens were harvested on day 4 post injury for
S1P analysis by LC-MS/MS. Results indicate S1P levels in spleen and injured quadriceps (quads) were significantly elevated with THI treatment.
Interestingly, uninjured quadriceps did not show a significant increase of S1P, whereas uninjured TA muscles did. *P <0.05 by student’s t-test.
Error bars represent SEM. CTX, cardiotoxin; IP, intraperitoneal; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MO, month-old; S1P,
sphingosine-1-phoshate; SEM, standard error of the mean; TA, tibialis anterior; THI, 2-acetyl-4(5)-tetrahydroxybutyl imidazole; wt, wild type.
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tered ad libitum. The vehicle consisted of water at pH
2.8 containing 10 g/l glucose.
Peripheral blood cell analysis
Blood was collected via retro-orbital blood collection
using heparinized capillaries and transferred to blood
collection tubes containing a final concentration of 1.6
mg/ml EDTA (SARSTEDT, Nümbrecht, Germany) for
analysis. Analysis of whole blood was undertaken with20 μl per sample using the Hemavet 950 FS system
(Drew Scientific, Dallas, TX, USA).
Analysis of gene expression by quantitative reverse
transcription-PCR (RT-PCR)
Total RNA (RNeasy Kit, Qiagen, Venlo, Netherlands)
was prepared from mdx4cv TA muscles homogenized
under liquid nitrogen by mortar and pestle. Methods for
RNA isolation and cDNA generation were in accordance
with manufacturer’s protocols using reverse transcriptase
Figure 2 (See legend on next page.)
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Figure 2 Dystrophic pathology following muscle injury is improved with THI treatment. (A) Experimental schematic of THI (0.075 μg/day)
and PBS (vehicle)-treated mdx mice injected IP twice daily for the first 72 hours following CTX injury. Muscles from aged mdx4cv mice (n = 7,
THI-treated: 3 × 11-MO females, 4 × 16-MO males; n = 6 vehicle-treated: 3 × 11-MO females, 3 × 16-MO males) were harvested for
histopathology analysis 18 days post CTX injury. (B) Histological quantification of picrosirius red staining indicates lower fibrotic accumulation
following injury in both TA and quadriceps (quads) muscles from mice treated with THI. For CTX-injected muscles, damaged regions of muscle
(for example fields with the greatest accumulation of sirius red staining) were quantified for both THI and vehicle-treated mice. The level of
fibrosis was not significantly different between treated and control (vehicle) uninjured quadriceps; however, uninjured TA muscles from 11-MO
THI-treated mice had lower fibrosis compared to control TA muscles. For each muscle, three separate sections (200 μm apart in longitudinal
distance) were analyzed. (C) Representative photographs of injured quadriceps stained with picrosirius red and fast green depict collagen
deposition (red staining), while muscle morphology and organization is depicted with hematoxylin and eosin staining. Scale bars = 50 μm.
(D) Oil Red O staining depicts fat deposits (arrows) over the entire CSA of THI-treated and vehicle-injured quadriceps from 16-MO males. Scale
bars = 500 μm. (E) The ratio of fat deposition in injured TAs over uninjured contralateral TAs quantified from Oil Red O staining was significantly
reduced in THI-treated versus control animals in 11-MO (*) but not 16-MO mdx4cv mice. In contrast, the ratio of injured over uninjured fat
deposits in quadriceps was significantly reduced in 16-MO (#) but not in 11-MO mdx mice. *P <0.05, **P <0.01 by student’s t-test. Error bars
represent SEM. CSA, cross-sectional area; CTX, cardiotoxin; IP, intraperitoneal; MO, month-old; SEM, standard error of the mean; TA, tibialis anterior;
THI, 2-acetyl-4(5)-tetrahydroxybutyl imidazole.
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ously described [13]. RNA (0.5 μg) was reverse tran-
scribed using the Omniscript RT Kit (Qiagen). For
reverse transcription-PCR (RT-PCR), 10 ng cDNA was
combined with SYBR Green (Thermo Scientific, Waltham,
MA, USA) following published conditions and primer
sequences for S1P-related genes by Grabski et al. [14]
and by Au et al. [15] for 18S.
Functional analysis: myography
Animals treated with THI or PBS (vehicle) via IP injec-
tion as aforementioned for 14 days were analyzed be-
tween 1 and 4 days following the final day of injection.
Prior to euthanasia animals were anesthetized with 0.5
mg/g weight avertin diluted in PBS. EDLs were then ex-
cised and equilibrated in Ringer’s solution (120 mM
NaCl, 4.7 mM KCl, 3.15 mM MgCl2, 1.3 mM NaH2PO4,
25 mM NaHCO3, 11 mM glucose, 1.25 mM CaCl2,
pH 7.2) with 95% O2/5% CO2 for a minimum of 15 mi-
nutes prior to stimulation [16]. For assessment of direct
S1P administration, EDL muscles from uninjured and
untreated 3.5-MO male mdx (C57BL/10ScSn-Dmdmdx/J)
were incubated with oxygenated Ringer’s solution
containing 10 μM S1P or vehicle (PBS with 4 mg/ml
fatty acid free BSA) for 15 minutes prior to stimulation
[16]. All functional experiments were carried out with
buffer solutions at 25°C under constant oxygenation.
Myography was conducted using a 820S myograph
(DMT, Ann Arbor, MI, USA) and data was recorded
using a PowerLab 4/30 acquisition system with LabChart
Pro software v7.3.1 (both from ADInstruments, Dunedin,
New Zealand). Stimulations were conducted with S88X
dual systems (Grass Technologies, Middleton, WI, USA).
Muscles were stimulated to establish optimal fiber
length (Lf ) and voltage at which maximum tetanic force
was measured at 120 Hz using 4.15 ms pulses within450 ms train duration [17]. Force frequency was carried
out using the same pulse duration at 10, 20, 40, 60, 80,
100 and 120 Hz, as outlined in the x-axis of Figure 3B.
Specific force was calculated as previously described
[18] by normalizing to the muscle cross-sectional area
(CSA). CSA is the quotient of dry muscle mass (mg)
over Lo (mm), which is defined as the product of Lf
with the fiber length ratio (0.44 for EDL) and mamma-
lian muscle density (1.06 mg/mm3).
Measurement of S1P in mouse tissue
S1P was quantified in tissue after homogenization and
extraction using liquid chromatography-tandem mass
spectrometry (LC-MS/MS). Tissue was pulverized in
liquid nitrogen using a mortar and pestle. Collected tis-
sue was weighed and an internal standard (C17 base
D-erythro-sphingosine-1-phosphate in methanol (Avanti
Polar Lipids, Alabaster, AL, USA)) was added at 1 pmol/
mg tissue. Tissue was then vortexed/extracted in 16 vol-
umes (mg/μl) of acetonitrile:water (80:20, v/v) for 10 mi-
nutes at room temperature. Supernatants were collected
after centrifugation (10 minutes at 14,000 rpm) and con-
centrated to dryness using a SpeedVac Concentrator
(Thermo Scientific). Pellets were resuspended in metha-
nol to a calculated concentration of 0.05 μM C17 base
D-erythro-sphingosine-1-phosphate. Then 10 μl was
analyzed by LC-MS/MS using C17 base D-erythro-
sphingosine-1-phosphate plus C18 base D-erythro-
sphingosine-1-phosphate (both at 0.05 μM) as a standard.
Separation of analytes was undertaken by liquid chro-
matography using a Chromolith RP-C18e 100 × 2 mm
column (EMD, Gibbstown, NJ, USA) and analysis by
tandem mass spectrometry with a Quattro Micro mass
spectrometer (Waters, Milford, MA, USA) in positive
ion mode. The HPLC gradient using two pumps was
linear from 50% MeOH to 99% MeOH using solvent A
Figure 3 (See legend on next page.)
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Figure 3 Elevating S1P levels with THI increases muscle fiber size. (A) Staining for laminin (green) and DAPI (blue) depict a dramatic
increase in muscle fiber size in both injured and uninjured quadriceps (quads) with THI treatment. Depicted are quadriceps muscles from 11-MO
mdx4cv mice. Scale bars = 50 μm. (B,C,D) Quantification of minimum muscle fiber diameter reveals a significant increase in myofiber size in THI-
treated animals. Increased myofiber diameter was observed in both (B) injured and (C) uninjured quadriceps from THI-treated 11-MO mdx4cv
mice, whereas only (D) uninjured quadriceps in THI-treated 16-MO mdx4cv mice showed increased myofiber size compared to vehicle controls. As
indicated by the distributions, mean and median values of muscle fiber minimum diameters, there is an overall increase in muscle fiber size with
THI treatment. Quantifications were undertaken in random fields in both injured and uninjured muscles in order to obtain an overall
representation of fiber size increase for each muscle.*P <0.05, ***P <0.0005 by student’s t-test. Error bars represent SEM. DAPI, 4',6-diamidino-2-
phenylindole; MO, month-old; S1P, sphingosine-1-phoshate; SEM, standard error of the mean; THI, 2-acetyl-4(5)-tetrahydroxybutyl imidazole.
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formic acid) over 1 minute at a flow rate of 0.35 ml/
min. To wash the column, the gradient was repeated
twice before equilibrating for 3 minutes before running
the next sample. The transitions analyzed were 380.25
>264.50 and 380.25 >82.00 for endogenous S1P, and
366.25 >250.50 and 366.25 >82.00 for internal standardFigure 4 S1P promotes functional improvement of mdx (C57BL/10ScS
14-day treatment of THI or PBS (vehicle) following CTX injury. THI was adm
Following treatment, EDL muscles were harvested and specific isometric fo
uninjured limbs. (B) Force frequency analysis reveals that EDL muscles isola
significantly greater specific force compared to injured vehicle controls (n =
mdx (C57BL/10ScSn-Dmdmdx/J) indicate specific force improved in injured bu
and untreated mdx (C57BL/10ScSn-Dmdmdx/J) EDL muscles with a high conc
specific force. *P <0.05, **P <0.005 by student’s t-test. Error bars represent S
sphingosine-1-phoshate; SEM, standard error of the mean; THI, 2-acetyl-4(5)with a dwell time of 0.07 seconds. Data collection was
by MassLynx software (Waters) and processed with
QuanLynx software (Waters).
Measurement of S1P in mouse plasma
S1P was quantified in plasma using butanol extraction
and liquid LC-MS/MS [19]. Internal standard (5 μl 3 μMn-Dmdmdx/J) muscle. (A) Experimental schematic of longer-term,
inistered following the aforementioned dose and injection regimen.
rce was analyzed by in vitro myography from both injured and
ted from injured limbs of THI-treated animals (n = 10) have
9). (C) Analysis of untreated and uninjured wt (C57BL/10ScSn) and
t not uninjured THI-treated EDL muscles. (D) Incubation of uninjured
entration of S1P (10 μM) leads to a significant increase in maximal
EM. CTX, cardiotoxin; EDL, extensor digitorum longus; S1P,
-tetrahydroxybutyl imidazole; wt, wild type.
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(Avanti Polar Lipids)) was added to 10 μl EDTA-
anticoagulated plasma and mixed thoroughly on an or-
bital shaker (Thermomixer, Eppendorf, Hauppauge, NY,
USA) for 10 minutes at 1,400 rpm at 20°C. The sample
was then acidified using 50 μl 30 mM citric acid/40 mM
Na2HPO4, pH 4.0, and extracted for 10 minutes at 1,400
rpm at 20°C with 125 μl water-saturated butanol (Fisher
Scientific, Waltham, MA, USA). The butanol layer was
removed and lyophilized in a centrifugal evaporator at
20°C. The residue was stored at −20°C until analyzed.
The residue was resuspended in 125 μl HPLC buffer A
(50% methanol, 1% formic acid, 5 mM ammonium
formate in water (JT Baker) and sonicated in a bath
sonicator for 1 minute at 20°C. Analytes in a portion of
the sample (10 μl) were then separated using liquid
chromatography (Shimadzu, Nakagyo-ku, Kyoto, Japan)
with a Luna 3 μm C18(2) 100Ǻ 50 × 2 mm column
(Phenomenex, Torrance, CA, USA) and analyzed by tan-
dem mass spectrometry on a 4000 QTRAP mass spec-
trometer (AB SCIEX, Framingham, MA, USA) in
positive ion mode. The HPLC gradient was linear from
buffer A to buffer B (10% isopropyl alcohol, 1% formic
acid, 5 mM ammonium formate in methanol) over 1 mi-
nute at a flow rate of 0.4 ml/min. To wash the column,
the gradient was repeated twice before equilibrating for
the next sample. The transitions analyzed were 380.3/
264.3 and 380.3/81.9 for endogenous S1P, and 366.2/
93.0, 366.2/82.0 and 366.2/250.3 for internal standard
with a dwell time of 15 milliseconds. Calibrators were in
mouse plasma (C18 base D-erythro-sphingosine-1-phos-
phate, Avanti Polar Lipids). Between-day coefficient of
variation was 7.7%. Pertinent instrument specific param-
eters were empirically derived and included curtain gas:
15, ion source voltage: 5000 V, emitter temperature: 550°C,
desolvation gas 1: 20, desolvation gas 2: 70, collision gas: 6,
entrance potential: 10, and collision cell exit potential: 10.
Chromatographic data were analyzed using Analyst 1.4.2
(AB SCIEX) by summing transitions for each analyte.
Creatine kinase (CK) assay
mdx4cv mouse plasma samples were diluted 1:50 and
total CK activity was measured by an enzymatic rate
method at the clinical laboratory of the Department of
Laboratory Medicine, University of Washington, using
the Beckman Coulter instrument (Brea, CA, USA) as
previously described [20]. Relative levels were then nor-
malized to body weight.
S1P injections
Right and left TAs of three 3-MO male mdx4cv:Myf5nlacZ/+
were injured once more with 10 nM CTX (Figure 5).
S1P (Enzo Life Sciences, Farmingdale, NY, USA;
Calbiochem) preparation was undertaken according tomanufacturer’s instructions. Briefly, S1P was dissolved
in methanol (0.5 mg/ml) and aliquoted, then the solvent
was evaporated with a stream of nitrogen to deposit a
thin film on the inside of the tube. Prior to use, aliquots
were resuspended in PBS with 4 mg/ml BSA (fatty acid
free) to a concentration of 500 μM. Directly following
CTX injection, 20 μl 500 μM S1P was injected in left
TAs, daily until day 3 post injury, at which time animals
were euthanized and muscles were harvested for freez-
ing. Right TAs were injected with an equal volume of
PBS with 4 mg/ml BSA as vehicle controls. In a separate
experiment (Figure 6), TAs of four 2.5-MO female
mdx4cv were injected with S1P or vehicle under the
same conditions stated above, in the absence of injury.
AJ/SCID mice (n = 4, 9-MO, B6. Cg-DysfprmdPrkdcscid/J)
were also injected for 3 days with S1P or vehicle in TAs
post CTX injury, following the same concentration and
injection regimen used in mdx4cv. For measurement of
S1P muscle content (Figure 7A) following intramuscu-
lar injections, 11-MO mdx4cv (n = 3) were injected 20 μl
500 μM S1P in left TAs and 20 μl vehicle in right TAs.
Muscles were harvested and frozen in liquid nitrogen
15 minutes post injection, and then processed using the
aforementioned methods for analyzing S1P in muscle
by LC-MS/MS. For injection of biotinylated-S1P, TAs
from 11-MO mdx4cv (n = 2) were injected intramuscu-
larly with 20 μl 500 μM S1P-biotin or vehicle (Echelon
Biosciences, Salt Lake City, UT, USA). TAs were
harvested and frozen in OCT compound 15 minutes fol-
lowing injection.
Mouse histology and immunohistochemistry
All mouse muscles were frozen directly in OCT com-
pound with liquid nitrogen cooled in isopentane and
sectioned 8 μm thick. Tissue for X-gal staining was fixed
for 10 minutes with 2% formaldehyde/0.2% glutaralde-
hyde and incubated overnight at 37°C with staining
buffer (PBS with 1 mg/ml X-gal, 5 mM potassium ferri-
cyanide, 5 mM potassium ferrocyanide, 2 mM CaCl2 (all
from Fisher Scientific)). Picrosirius red with fast green,
hematoxylin and eosin, and Oil Red O staining were
conducted following established protocols [21]. Fibrosis
was quantified as percentage of area stained red within
each 20 × field analyzed using ImageJ v1.40 or Adobe
Photoshop CS2 (San Jose, CA, USA). For evaluating fi-
brosis, the mean value from three separate sections (200
μm apart in longitudinal distance) were analyzed from
each muscle and used to calculate the overall mean for
each muscle group outlined in the x-axis of Figure 1D.
Lipid accumulation was quantified with the ImageJ cell
counter plugin by counting fatty infiltrates in montages
(stitched from 10 × photos) covering the entire CSA of
each muscle. Muscles injected with S1P-biotin or vehicle
were cut 8 μm thick, fixed for 5 minutes with 4%
Figure 5 Direct administration of S1P promotes muscle regeneration following acute injury. (A) Experimental schematic of S1P and PBS
(vehicle) injected daily for the first 72 hours into TAs of 3-MO mdx4cv:Myf5nlacZ/+ mice (n = 3, left TAs injected S1P, right TAs injected PBS)
following CTX injury. (B) Top row: X-gal staining reveals an increased number of β-galactosidase+ nuclei at the sites of injury in S1P-treated TA
muscles compared to vehicle controls. Bottom row: staining for eMyHC with DAB reveals a significant increase in the number of newly
regenerated muscle fibers in S1P-treated TA muscles. Scale bars = 50 μm. (C) Left graph: quantification of β-galactosidase+ nuclei indicates the
number of Myf5+ cells is significantly increased at the site of injury in S1P-treated compared to untreated muscles. Middle graph: a significant
increase in β-galactosidase+ nuclei was also observed over the entire CSA of each S1P-treated TA muscle. Right graph: quantification of the
number of eMyHC fibers within areas of regeneration was significantly greater with S1P treatment. *P <0.05 by student’s t-test. Error bars
represent SEM. CSA, cross-sectional area; CTX, cardiotoxin; DAB, 3,3'-diaminobenzidine; eMyHC, embryonic myosin heavy chain; MO, month-old;
S1P, sphingosine-1-phoshate; SEM, standard error of the mean; TA, tibialis anterior.
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gated to Alexa Fluor 594 (Life Technologies, Carlsbad,
CA, USA) at 1:1000 in PBS and 1% BSA for 1 hour.
Immunohistological staining
Staining was undertaken using freshly frozen mdx4cv
muscles. Pax7 staining was performed as outlined by
Clever et al. [22] with slight modification. Sectionswere fixed overnight in 4% formaldehyde (from parafor-
maldehyde powder) at 4°C. Following fixation, antigen
retrieval was performed with 10 mM citrate buffer
(with 0.05% Tween 20 at pH 6.0) warmed in a water
bath at 90°C for 20 minutes. Slides were then perme-
ated with ice cold methanol for 5 minutes at room
temperature. Streptavidin/biotin blocking (Vector Labora-
tories, Burlingame, CA, USA) was performed according to
Figure 6 Administration of S1P leads to increased levels of S1PR1 and P-rpS6 in vivo. (A) Experimental schematic of S1P and PBS (vehicle)
injected daily for the first 72 hours into TAs of uninjured mdx4cv mice (n = 4, 2.5-MO, left TAs injected S1P, right TAs injected PBS). (B) Western
blot analysis of injected TAs (n = 3, 2.5-MO mdx4cv) indicates that administration of S1P significantly increases S1PR1 levels. (C) Western blot
analysis of injected TAs (n = 4, 2.5-MO mdx4cv) for total, and P-Akt, P-mTOR and P-rpS6, reveals that total and P-rpS6 were significantly higher with
S1P treatment. Increased levels of total and P-rpS6 suggest that S1P administration promotes protein synthesis in mdx muscles. *P <0.05 by
student’s t-test. Error bars represent SEM. MO, month-old; P-Akt, phosphorylated Akt; P-mTOR, phosphorylated mammalian target of rapamycin;
P-rpS6, phosphorylated ribosomal protein S6; rpS6, ribosomal protein S6; S1P, sphingosine-1-phoshate; S1PR1, S1P receptor 1; SEM, standard error
of the mean; TA, tibialis anterior.
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the Mouse on Mouse (MOM) Kit (Vector Laboratories)
with immunoglobulin G (IgG) blocking for 5 hours at 4°C
prior to addition of mouse monoclonal anti-Pax7 (clone
PAX7, R&D Systems, Minneapolis, MN, USA) diluted at
1:20 and incubated overnight at 4°C. Biotinylated anti-
mouse secondary was supplied with and used as pre-
scribed by MOM Kit instructions. Streptavidin conjugated
to Alexa Fluor 488 (Life Technologies) was added at
1:1000. As a negative control for Pax7 staining, a mouse
IgG isotype was applied to separate ribbons and treated in
parallel. For BS1 staining, muscles were initially fixed with
4% formaldehyde for 5 minutes at room temperature then
stained with BS1 directly conjugated to fluorescein iso-
thiocyanate (FITC), diluted at 1:400 in PBS with 1% BSA
and applied for 1 hour at room temperature. Following
BS1 staining, wheat germ agglutinin (WGA) directly con-
jugated to rhodamine was administered at 1:400 dilution
as a counterstain for identifying myofibers. CD3e staining
was undertaken in the same manner as BS1, using ratmonoclonal anti-CD3e (clone 145-2C11, eBioscience, San
Diego, CA, USA) at 1:100 dilution, followed by anti-rat
IgG conjugated to Alexa Fluor 594 at 1:1000 dilution.
For laminin staining, tissue was also fixed with 2% for-
maldehyde for 5 minutes then treated with polyclonal
rabbit anti-laminin (Sigma-Aldrich, St Louis, MO, USA)
for 1 hour at 1:400 dilution in PBS and 1% BSA. Follow-
ing washes, Alexa Fluor 488 conjugated goat anti-rabbit
IgG (Life Technologies) was administered at 1:800 dilu-
tion for 1 hour. Controls omitting the primary antibody
were included with all staining. For embryonic myosin
heavy chain (eMyHC), tissue was first fixed with 2% for-
maldehyde for 5 minutes, treated with streptavidin/
avidin blocking and blocked with IgG block from MOM
Kit for 5 hours at 4°C. Following blockade, concentrated
mouse anti-eMyHC (clone F1.652, received concen-
trated at 357 μg/ml IgG, Developmental Studies Hybrid-
oma Bank (DSHB), University of Iowa, IA, USA) was
administered at 1:400 dilution overnight at 4°C. The
remainder of the staining was undertaken following
Figure 7 (See legend on next page.)
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Figure 7 Direct injection results in elevated S1P levels which correlate with the activation of receptor 1 in muscle fibers. (A) To quantify
the elevation of S1P following direct administration, we injected a single dose (same dose as Figure 5) of S1P in left TAs and vehicle in right TAs
of uninjured mdx4cv (n = 3, 11-MO) mice. TA muscles were harvested 15 minutes post injection for analysis by LC-MS/MS. Results indicate a
significant elevation of S1P following direct injection. (B) To visualize the location of S1P following injection, biotinylated-S1P was injected in left
TAs versus vehicle in right TAs of uninjured mdx4cv mice (n = 2, 11-MO). Once more, TAs were harvested 15 minutes following injection. Staining
with streptavidin conjugated to Alexa Fluor 594 reveals the presence of S1P-biotin around the perimeter of muscle fibers. (C) Staining of mdx4cv
TAs for S1PR1 and S1PR3 reveals S1PR1 is localized to the perimeter and perinuclear area (arrow) of muscle fibers (left photo). In contrast, staining
for S1PR3 was mainly localized to the muscle vasculature (middle photo). Staining in parallel with an IgG isotype control for both antibodies
shows the absence of non-specific staining (right graph). (D) Staining for S1PR1 in CTX-injured TAs (same tissue from Figure 5) reveals S1PR1 is
present at the perimeter and perinuclear area of regenerating eMyHC+ fibers. (E) Staining for phosphorylated S1PR1 in the same mdx4cv TAs was
more prominent in the perinuclear area of eMyHC+ fibers, indicating the presence of active S1PR1 signaling in regenerating fibers. Scale
bars = 50 μm. **P <0.005 by student’s t-test. Error bars represent SEM. CTX, cardiotoxin; eMyHC, embryonic myosin heavy chain; IgG,
immunoglobulin G; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MO, month-old; S1P, sphingosine-1-phoshate; S1PR1, S1P
receptor 1; S1PR3, S1P receptor 3; SEM, standard error of the mean; TA, tibialis anterior.
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(DAB) was used for visualizing and quantifying eMyHC
fibers. For fluorescence, eMyHC was visualized using
streptavidin conjugated to Alexa Fluor 594 used at
1:1000 dilution for 1 hour. For S1P receptor staining,
slides were fixed with 4% formaldehyde for 5 minutes
and stained with rabbit polyclonal IgG antibodies
against S1PR1, S1PR3 (Cayman Chemical, Ann Arbor,
MI, USA) and phosphorylated S1PR1 (raised against
Thr236, Assay Biotechnology, Sunnyvale, CA, USA), all
applied at a dilution of 1:200 for 2 hours. Following re-
ceptor staining, goat anti-rabbit IgG conjugated to Alexa
Fluor 488 was added at 1:1000 for 1 hour. In parallel, we
stained additional slides with rabbit polyclonal IgG isotype
at the same final concentrations to exclude non-specific
staining of these antibodies in mdx4cv muscles.
Staining quantifications were all undertaken using
ImageJ cell counter plugin. Calculations, statistics and
graphs were generated with Microsoft Excel (Redmond,
WA, USA). Bright field photographs were captured using
either a Fisher Scientific Micromaster digital inverted or
upright microscopes with Micron software. Fluorescent
photographs were captured with a monochromatic camera
using an Axiovert 200 microscope (Zeiss, Oberkochen,
Germany). Individual fluorescent channels were colored
and merged using Adobe Photoshop. Brightness contrast
levels were adjusted to increase visibility and reduce back-
ground in most photographs.
Western blot analysis
Tissue for western blot analysis was snap frozen in liquid
nitrogen and subsequently homogenized. Freshly iso-
lated TA muscles were harvested and snap frozen in li-
quid nitrogen prior to homogenization with disposable
tissue grinders. Tissue was homogenized under liquid
nitrogen then resuspended in lysis buffer containing
50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl,
5 mM NaF, 0.25% (w/v) sodium deoxycholate, 2 mM
NaVO3, 1% Triton X-100 (v/v), supplemented withcomplete protease inhibitor cocktail (Roche, Basel,
Switzerland), and complete phosphatase inhibitor cocktails
1 and 2 (Sigma-Aldrich). Protein extracts were separated
using Ready Gel Tris–HCl (BioRad, Hercules, CA, USA),
4 to 20% linear gradient and transferred to polyvinylidene
fluoride (PVDF) membranes with a wet transfer system
(BioRad). Membranes were blocked for 1 hour with
Tris-buffered saline with 0.1% (v/v) Tween 20 containing
5% (w/v) BSA. For S1PR1 analysis, rabbit polyclonal
anti-S1PR1 was used at a 1:500 dilution (Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Rabbit polyclonal anti-
bodies were used to blot against phosphorylated (Thr308)
Akt, total Akt, phosphorylated (Ser2448) mammalian tar-
get of rapamycin (mTOR), total mTOR, phosphorylated
(Ser240/Ser244) rpS6, total rpS6 (1:1000, Cell Signaling
Technology, Danvers, MA, USA) and β-actin (1:10000,
Sigma-Aldrich). The signals were detected using an en-
hanced chemiluminescence kit (Millipore, Billerica, MA,
USA) and CL-XPosure films (Thermo Scientific) were an-
alyzed using ImageJ.
Statistics
Student’s t-test was used to determine statistical signifi-
cance for the majority of experiments. P values gener-
ated by analysis of variance (ANOVA) are specified in
the text.
Results
Alterations of S1P regulation and content following IP
injection of THI in mdx mice
To determine the effect of elevating S1P levels in dys-
trophic animals, we studied the effects of THI in the
mdx mouse model for DMD [23,24]. Recently, Loh et al.
(2012) showed that compared to wt, mdx muscles are in
a state of S1P deprivation as they exhibit increased levels
of the enzymes that degrade S1P (S1P lyase and S1P
phosphatase 1) [8]. THI is a hydrophilic small molecule
that increases S1P levels by inhibiting the lyase that irre-
versibly degrades S1P [11,25,26]. In turn, low doses of
Ieronimakis et al. Skeletal Muscle 2013, 3:20 Page 13 of 21
http://www.skeletalmusclejournal.com/content/3/1/20THI may be sufficient to cause mild lymphocytopenia but
the presumable increase of S1P levels in muscle have not
been reported [8,11]. To corroborate the effects of THI in
mdx4cv mice, we analyzed changes in lymphocytes before
and after treatment, and measured S1P content in muscle
(Figure 1). THI has low oral bioavailability; Bagdanoff et
al. showed 10 to 12% bioavailability of THI when adminis-
tered orally [10]. Thus we evaluated IP injections of THI
as a parenteral delivery route for elevating systemic levels
of THI. Peripheral blood was collected and analyzed be-
fore and 12 hours after two IP injections of THI (each in-
jection was 250 μl 0.15 mg/ml THI, administered 6 hours
apart). Following THI treatment, we observed a significant
drop of all leukocytes except monocytes in mdx4cv (n = 3,
1.5-MO) (Figure 1A). Of note, prior to treatment with
THI, the total number of white blood cells and amount of
individual leukocyte populations except monocytes, was
significantly elevated in 1.5-MO mdx4cv mice (n = 3) ver-
sus age-matched wt mice (n = 4). Interestingly, the num-
ber of platelets was also elevated twofold in mdx4cv versus
wt, but declined to near wt following THI administration
(Additional file 1: Figure S1). This systemic effect in
lymphocyte count indicates that THI functions efficiently
when delivered systemically via IP injection. In addition,
for short-term treatments, IP administration is desirable
to ensure that all mice received the same dose. Thus for
the majority of experiments described herein, we opted to
administer THI via IP administration.
Loh et al. also demonstrated that following acute in-
jury, the expression of S1P lyase increases in wt muscle
[8]. Thus we analyzed the expression of enzymes that
regulate S1P production and degradation following CTX
injury in the mdx background with and without THI
treatment. Right TA and quadriceps muscles were unin-
jured, while left counterparts were injured using CTX, a
well characterized model of acute injury where initial
muscle destruction is followed by a rapid myogenic re-
sponse [27-30]. mdx4cv mice (n = 6, 3.5-MO males) were
injected IP immediately following CTX and thereafter
five additional times during a 3-day period (for example
2 × IP injections per day) with either the previously used
dose of THI or vehicle. For this analysis, muscles were
harvested at day 4 post injury; the peak of myogenic
gene expression following CTX-induced damage [28]. In
the absence of THI, expression of the S1P lyase was sig-
nificantly elevated following injury (Additional file 1:
Figure S2A). Surprisingly, expression of S1P phosphatase
1 and lyase were greater in the injured muscles with THI
treatment, suggesting a possible compensation in the
S1P degradation pathways in response to the inhibition
of the S1P lyase. Analogous to these results, expression
levels of S1P kinase 1 were also increased with injury and
at higher levels with THI (Additional file 1: Figure S2B).
In contrast, the expression of S1P kinase 2 was onlysignificantly elevated in the injured muscles from THI-
treated animals. These results suggest that acute injury
in mdx4cv muscles induces upregulation of enzymes that
regulate S1P metabolism. In turn, elevated expression of
both S1P kinases with THI treatment may be beneficial
for muscle regeneration in mdx mice. However, with
THI treatment S1P phosphatase 1 and lyase expression
were also greatly increased. Therefore we examined S1P
content, to determine if THI treatment results in in-
creased intramuscular S1P levels and in turn promotes
muscle regeneration following CTX injury.
In order to determine if THI treatment results in in-
creased intramuscular S1P levels, a second group of
mdx4cv animals was treated with THI or PBS (n = 6,
5-MO males), following the same dosing schedule (2 × IP
injections per day for the first 3 days post CTX injury) and
sacrificed at day 4 to analyze the efficacy of THI in
increasing S1P levels (Figure 1B). In concordance with
published work, treatment with THI increased S1P levels
in spleen but not plasma (Figure 1B, Additional file 1:
Figure S3A) [10,11]. S1P levels were also significantly in-
creased in CTX-injured quadriceps from THI-treated ani-
mals (Figure 1B). This indicates that despite increased
expression of S1P phosphatase 1 and lyase following in-
jury, the counteracting increased expression of both S1P
kinases results in elevated levels of intramuscular S1P. In
addition, we also observed increased S1P levels in the un-
injured TA muscles from mice treated with THI compared
to vehicles. To examine if such extravascular increases of
S1P correlated with a beneficial effect in dystrophic mice,
we analyzed the level of plasma CK, which are elevated in
humans and mice with muscular dystrophy activity in the
same group of THI-treated mdx4cv mice [31]. Results indi-
cate a trending, but not statistically significant decline in
CK activity levels in plasma collected on day 4 post injury
from THI versus vehicle-treated mice (Additional file 1:
Figure S3B).
Reduction of dystrophic muscle pathology in acutely
injured mdx muscles via administration of THI IP
Although young mdx mice exhibit robust muscle repair,
regeneration becomes impaired with aging, resulting in
muscle atrophy and dystrophy [3]. Therefore, in a third
experiment, the effects of THI on histopathology were
assessed in injured and uninjured muscles from two
groups of aged mdx4cv mice (n = 6, 11-MO females; n = 7,
16-MO males), to determine the effects of increasing
levels of S1P in dystrophic animals at a stage of severe
muscle wasting. Importantly, it has been reported that
mdx females older than 6 months of age exhibit greater fi-
brosis than males [32]. Once more, right TA and quadri-
ceps muscles were uninjured, while left counterparts were
injured with CTX (Figure 2A). Regeneration following
CTX injury is well orchestrated in normal muscle but
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studies we analyzed the muscles from 11- and 16-MO
mdx mice 18 days following CTX injury, a time point
expected for non-diseased muscles to fully regenerate
[28]. In the 16-MO mice, muscles were weighed imme-
diately after collection and normalized to body weight
(grams muscle weight over grams mouse weight). As
expected, injured muscles were lighter than uninjured
muscles in vehicle mice, an approximate weight loss
greater than 20% (Additional file 1: Figure S4A). However,
in the THI-treated mice the weight of injured quadriceps
was similar to uninjured quadriceps (muscle weight
ratio injured/uninjured approximates one), suggesting
that THI treatment promotes muscle repair and pro-
tects from muscle loss following acute injury.
Fibrosis and fat deposition are both hallmarks of muscle
wasting and dystrophic muscle pathology [32,33]. In
addition, when regeneration is impaired, fibrosis and fat
accumulate in place of muscle following acute injury
[34,35]. Histological quantification revealed that THI
treatment reduced accumulation of both fibrosis and fat
deposition following acute injury in quadriceps and TA
muscles (Figure 2B,C). Results for lower fibrosis were con-
firmed by third party hydroxyproline analysis of injured
TAs from 16-MO animals (Additional file 1: Figure S4B).
Interestingly, fibrosis was also significantly lower in unin-
jured TAs of 11-MO females, which correlates with the
capacity of THI to elevate S1P levels in uninjured TAs
(Figure 1B, Additional file 1: Figure S5). Although only left
TAs and quadriceps were injected with CTX, fibrosis ac-
cumulation in uninjured muscles was likely elevated as
mice disuse injured limbs and bear most of the use/weight
on the uninjured contralateral limb. Therefore, the differ-
ences observed in uninjured TAs are likely due to reduc-
tions in the amount of fibrotic deposition that would
otherwise accumulate without THI treatment, since it is
unlikely THI can reverse already accrued fibrosis. Along
with lower fibrosis observed in injured muscles, the overall
morphology appeared more organized with THI treatment
compared to vehicle-treated animals (Figure 2C). In
addition, the number of EBD-positive fibers, an indicator
of muscle fiber damage, was lower in injured 11-MO mus-
cles and significantly reduced in uninjured 11-MO quadri-
ceps (Additional file 1: Table S1) [12,36]. In these muscles
the number of centrally nucleated fibers was comparable
between THI and vehicle-treated animals (Additional
file 1: Figure S6).
To test whether THI-treated mice show decreased fat
deposition in injured muscles, we quantified the fat de-
posits within entire cross-sections of THI and vehicle-
treated muscles (Figure 2D). The ratio of fat deposits
between injured and uninjured contralateral muscles
was then compared to THI and vehicle-treated mice
(Figure 2E). This analysis indicates that THI significantlyreduced fat deposition resulting from injury in 11-MO
female TAs and 16-MO male quadriceps. These results
demonstrate that THI treatment reduces injury-induced
fat deposition and fibrosis in mdx muscles.
Further analysis of THI-treated mdx4cv mice revealed an
increase in muscle fiber size in quadriceps (Figure 3A).
Although mdx mice undergo muscle hypertrophy as com-
pared to wild type, we observed a significant increase in
the minimum fiber diameter with THI treatment in dia-
phragms, and in both uninjured and injured quadriceps of
11-MO mice (Figure 3B,C and Additional file 1: Figure S7)
[37]. Uninjured quadriceps of THI-treated 16-MO males
also showed a significant increase in fiber size (Figure 3D).
In summary, 3 days of THI treatment is sufficient to in-
crease muscle fiber size in older mdx mice.
To assess if increases in muscle fiber size observed with
THI treatment are accompanied by an increase in the
number of satellite cells, we quantified the number of
Pax7+ cells. Within skeletal muscle, Pax7 is specifically
expressed by satellite cells, which have been reported to
decline in older mdx4cv muscles [38-40]. As expected, few
satellite cells (Pax7+ nuclei) were visible in cross-sections
of 11-MO mdx muscles. However, there was a significant
increase in the mean number of Pax7+ nuclei, collectively
in limb muscles (TAs and quadriceps) from THI-treated
11-MO animals (Additional file 1: Figure S8).
S1P is a potent angiogenic factor [41-43]. Thus we
studied the effects of THI treatment on the skeletal
muscle microvasculature. We quantified the number of
vessels using BS1, a lectin that highlights endothelial
cells [44]. In contrast to the increase in Pax7+ cells, we
did not observe an increase in BS1+ vessels in injured
11-MO TA muscles. Quantitative RT-PCR analysis of
endothelial related genes eNOS and CD31 in 5-MO
mdx4cv TA muscles at day 4 post injury, show no signifi-
cant difference in the levels of expression of these endo-
thelial associated genes in THI treatment compared to
vehicle (Additional file 1: Figure S9). This suggests that
THI benefits on muscle repair do not depend on in-
creasing microvasculature density.
THI treatment elevates isometric force in acutely injured
mdx EDL muscles
To assess if increasing S1P levels promotes dystrophic
muscle function, in a fourth experiment we conducted
myography analysis following longer treatment with
THI. For this experiment, another group of mdx mice
(male 4.75- to 5-MO C57BL/10ScSn-Dmdmdx/J) was in-
jured and treated with daily IP injections using the same
THI dose and injection interval, for 14 consecutive
days; the maximum duration for IP administration
allowed by our approved animal protocol. Animals were
treated with THI (n = 10) or vehicle (n = 9) for 14 days
following injury, and analyzed between day 15 and 19
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contralateral limbs were analyzed for isometric specific
force; a physiological measurement of muscle force that
is reduced with muscular dystrophy in mice and
humans [18,45,46].
To assess if the EDL is damaged as a consequence of
CTX injection in the TA, we injured and analyzed a sep-
arate group of mdx mice (n = 4) 12 hours post injury.
For this fifth experiment, CTX injections included India
ink to label needle penetration [47]. To assess muscle
fiber damage, a consequence of CTX injury, animals
were injected IP with EBD immediately following CTX
injection. The presence of EBD indicates EDL muscles
are damaged. However, EDL damage is not due to direct
penetration by the needle since India ink was only
present in the CTX-injected TA muscles (Additional file 1:
Figure S10).
Force frequency analysis revealed a significantly higher
specific force by EDL muscles isolated from injured
limbs of THI-treated mice (Figure 4B). These values
were similar to EDL muscles isolated from contralateral
uninjured limbs, indicating that THI prevented wasting
and preserved muscle function following acute injury
(Figure 4B). However, the specific force observed after
THI treatment was still lower than wt control animals
(Figure 4C). Two weeks of THI treatment was not suf-
ficient to improve specific force in uninjured EDL mus-
cles. However, as shown in Figure 1B, the THI dose of
0.75 μg/day used for all our experiments does not sig-
nificantly raise S1P levels in all uninjured mdx muscles.
In addition, although peripheral lymphocytes declined
with THI (Figure 1A), we did not observe a decline of
CD3e+ T-cells present in the diaphragm following 2
weeks of THI (Additional file 1: Figure S11) [48].
Therefore, it is plausible that a higher dose of THI is
required to sufficiently elevate S1P levels needed to
improve specific force in uninjured mdx muscles.
However, since THI is insoluble in PBS at higher con-
centrations and has low oral bioavailability, we chose to
directly study the effects of high levels of S1P on unin-
jured mdx muscles ex vivo. For this experiment, EDLs
from uninjured and untreated mdx mice were analyzed
following incubation with 10 μM S1P [16]. Analysis of
the maximal specific force indicates that direct admin-
istration of S1P significantly increases force output in
uninjured mdx muscle (Figure 4D). Such results indi-
cate that treatment with high concentrations of S1P
can promote functional improvement of dystrophic
muscles.
Overall, reduction in fibrosis and fat deposition, and
increase in myofiber size and satellite cell numbers, indi-
cate that elevating S1P levels, pharmacologically or by
direct administration, has a profound benefit in dys-
trophic muscle repair and function.Direct administration of S1P promotes muscle
regeneration in mdx mice following CTX injury
S1P is essential for satellite cell turnover, myoblast dif-
ferentiation and muscle regeneration in non-diseased
mice, and more recently shown to promote satellite cell
activation in mdx muscle [4,5,8,47]. To determine if the
increase in satellite cell number observed in the THI-
treated muscles was a result of increased S1P muscle
content, we examined the effects of direct S1P adminis-
tration following CTX-induced acute injury in dys-
trophic muscles. In order to identify satellite cells and
their progeny, we utilized mdx4cv:Myf5nlacz/+ mice carry-
ing the nuclear lacZ reporter driven by the endogenous
Myf5 gene, a marker of myogenic cells [49-51]. CTX was
applied to both TA muscles (n = 3, 3-MO mdx4cv:
Myf5nlacz/+ males), then S1P was immediately injected
intramuscularly into left TAs and a vehicle control into
right TAs. Injections were repeated daily for the first
72 hours following injury and TAs were harvested on
day 4 post injury, directly following the peak of injury-
induced myogenic cell proliferation for analysis of
Myf5+ nuclei (Figure 5A) [28]. S1P-treated muscles
showed a dramatic, fourfold increase in the number of
Myf5+ nuclei in areas with severe CTX damage com-
pared to vehicle controls (Figure 5B top row and 5C left
graph). Furthermore, a significant increase in the number
of Myf5+ nuclei was observed over the entire CSA of S1P-
treated TAs (Figure 5C middle graph, Additional file 1:
Figure S12). These data demonstrate that S1P treatment
increases the number of myogenic cells in mdx muscles
following injury and suggests that S1P promotes satellite
cell proliferation in vivo.
We then determined whether the increase in myo-
genic cells promotes dystrophic muscle repair by stain-
ing for eMyHC, a marker of regenerating muscle fibers
[27]. In concurrence with the rise of Myf5+ myogenic
cells, a 3.6 fold increase in the number of eMyHC+ fibers
was observed in S1P-treated TAs (Figure 5B bottom
row, 5C right graph). This increase in eMyHC+ fibers,
corresponded with elevated numbers of centrally nucle-
ated muscle fibers in the injured regions of S1P-treated
muscles (Additional file 1: Figure S13A). Furthermore,
the size of regenerating myofibers in S1P-treated TAs
was significantly greater, as indicated by the minimum
diameter quantified for the largest eMyHC+ fibers
(Additional file 1: Figure S13B). Collectively, these data
show that local administration of S1P promotes dys-
trophic muscle repair by improving satellite cell re-
sponse and contribution to muscle fiber regeneration.
S1P directly acts on mdx muscle fibers, and elevates
levels of total and phosphorylated S1PR1
In mammals there are five S1P receptors that share
homology to G-protein coupled receptors [52]. It has
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cifically activated in myogenic cells and that downstream
effectors of S1P action in satellite cells include compo-
nents of the JAK-STAT signaling pathway [8]. In contrast,
our results and others, of exogenous S1P treatment
resulting in increased EDL force, suggests that S1P also
acts directly on muscle fibers [16]. The amount of exogen-
ous S1P added in the bath was super-physiological and
thus we measured S1P muscle levels following intramus-
cular injection of S1P. In this experiment, left TAs from
mdx4cv mice (n = 3, 11-MO) were injected with the same
dose of S1P as the mdx4cv:Myf5nlacz/+ mice depicted in
Figure 5A, while contralateral TAs received the same ve-
hicle. In contrast to the previous experiment depicted in
Figure 5A, TA muscles were injected in the absence of in-
jury and were harvested for S1P analysis 15 minutes post
injection (Figure 6A); the same time used for S1P incuba-
tion prior to EDL force measurement shown in Figure 4D.
Results indicate that within this timeframe, intramuscular
injection of S1P does significantly increase S1P levels in
mdx muscle (Figure 6A).
To directly observe where S1P binds in the muscle, a
separate group of mdx4cv (n = 2, 11-MO) were injected
with the same amount of biotinylated-S1P in left and ve-
hicle in right TAs. Once more, TAs were harvested 15
minutes post injection for histological visualization of
S1P. Staining with streptavidin conjugated to Alexa
Fluor 594 reveals that biotinylated-S1P is present in
many cells, but particularly localized to the perimeter of
muscle fibers (Figure 5B). Among the three S1P recep-
tors (S1PR1, S1PR2, S1PR3) expressed in muscle, S1PR3
and S1PR1 are the most abundant in wt muscle [5]. Im-
portantly, expression of these three S1P receptors is re-
duced in mdx muscle cells, especially S1PR1, which
shows more than five fold reduction in relative mRNA
levels (Additional file 1: Figure S14). Staining of mdx4cv
muscles (3.5-MO) for S1PR1 and S1PR3, reveals that
S1PR1 is present at the perimeter of muscle fibers and
myonuclei, whereas S1PR3 appears localized to the
vasculature (Figure 6C). S1PR1 is a G protein-coupled
receptor (GPCR) that can be activated via phosphoryl-
ation, resulting in translocation to the endosomal com-
partment and/or the perinuclear compartment [53-55].
Therefore, perinuclear localization of S1PR1 suggested
that in response to S1P treatment, receptor 1 signaling is
activated in mdx4cv muscle fibers. To evaluate the pres-
ence of active S1PR1 signaling during muscle fiber re-
generation, we surveyed the same CTX-injured muscles
depicted in Figure 5A for the presence of phosphory-
lated S1PR1. Results indicate S1PR1 is localized around
the perimeter of muscle fibers and intracellularly near or
within the myonuclei (perinuclear) of newly regenerated
eMyHC+ fibers (Figure 6D). In parallel, we observed
more concentrated staining for phosphorylated S1PR1localized perinuclearly and less so around the perim-
eter of eMyHC+ fibers (Figure 6E). These results indi-
cate that S1PR1 signaling is active in regenerating
muscle fibers and suggests that the beneficial actions
that S1P exerts on mdx muscle fibers may be mediated
through S1PR1.
S1P administration correlates with increased levels of
S1PR1 and P-rpS6, an indicator of protein synthesis
S1PR1 has been implicated in myoblast proliferation
and shown to steadily increase during the course of re-
generation in non-diseased muscle [4,5]. Therefore to
gain more insight on the potential action that S1P ex-
erts via S1PR1 in dystrophic muscle, we injected S1P in
uninjured TAs of mdx4cv (n = 3, 2.5-MO), and quanti-
fied the level of S1PR1 and some downstream effectors
(Figure 7A) [56]. In turn, S1P treatment resulted in
significantly elevated levels of S1PR1 in mdx4cv TAs
(Figure 7B). In a separate experiment, we injected S1P
in left TAs and vehicle in right TAs of mdx4cv (n = 3,
10-MO), following the same dose and experimental de-
sign (three injections, one per day, harvest on day 4),
and analyzed TA muscles for phosphorylated S1PR1.
Results from this experiment show that phosphorylated
S1PR1 is also significantly elevated with S1P treatment
(Additional file 1: Figure S15).
A result of S1P injection was larger eMyHC+ fibers
that were positive for phosphorylated S1PR1 (Figure 6E,
Additional file 1: Figure S13B). Therefore, we examined
if elevated S1PR1 levels corresponded with known regu-
lators of cell size and protein synthesis; Akt, mTOR, S6
kinase and rpS6. S1P-induced hypertrophy has been
described in cultured cardiomyocytes, which was ac-
companied by activation of Akt and S6 kinase [57]. In
addition, S1PR1 activation of S6 kinase via a Gi-
dependent pathway has been reported in vascular
smooth muscle cells [56]. Akt and mTOR signaling via
S6 kinase, an activator of rpS6 implicated in protein
synthesis, has been described as sufficient to induce
skeletal muscle hypertrophy [58-60]. Therefore, we
evaluated if direct injection of S1P induces activation of
these pathways in uninjured TA muscles of mdx4cv mice
(n = 4, 2.5-MO). Western blot analysis of TA muscles
injected for 3 days with S1P (Figure 7A) revealed that
the levels of phosphorylated Akt (P-Akt) and mTOR
(P-mTOR), though increased, were not significantly
higher in S1P-treated muscles (Figure 7C). However, the
levels of rpS6 and phosphorylated rpS6 (P-rpS6) were
significantly increased with S1P treatment compared to
control muscles, suggesting an increase in protein syn-
thesis. Although a more detailed study is required to
elucidate the role of S1P in skeletal muscle protein syn-
thesis, our data suggest that S1P can activate muscle
anabolic pathways in the mdx mouse.
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in dysferlinopathy mice following acute injury
The role of dysferlin is currently unknown, but its ab-
sence in humans and mice results in chronic muscle
wasting that primarily affects limb and girdle muscles
[61-63]. Although dysferlinopathy is less severe than
DMD [64], dysferlinopathy patients are often wheelchair
bound between 30 and 40 years of age [65]. Much like
DMD, muscles in humans and mice lacking functional
dysferlin exhibit chronic atrophy, resulting in the accu-
mulation of fibrosis and fat [66]. Therefore we tested the
effects of S1P administration after CTX injury in a
model of dysferlinopathy (AJ/SCID) to evaluate if the
benefits of S1P are exclusive to the mdx background or
can be applied to other muscle wasting diseases [67].
We followed the same experimental design outlined in
Figure 5A, injecting left TAs of AJ/SCID mice (n = 4,
9-MO) with the same dose of S1P and vehicle in right
TAs for 3 days following CTX injury. In contrast to the
experiments in mdx4cv, we harvested TAs on day 6 post
injury in order to also evaluate the onset of fibrosis. In
accordance to the results observed in mdx, we observed
improved muscle regeneration with the administration
of S1P in AJ muscles. Specifically, we observed lower
fibrosis and increased centrally nucleated fibers, as well
as improved muscle architecture in the damaged regions
of muscle with S1P administration (Additional file 1:Figure 8 Longer-term treatment with THI elevated muscle force in un
treatment regimen. Beginning at 4 weeks of age, mdx4cv mice (1-MO males) w
(n = 3) in drinking water. (B) Myography analysis of EDL muscles reveals a sig
by student’s t-test. Error bars represent SEM. (C) Summary of findings: S1P can
but also enhance muscle fiber size and force, possibly through S1PR1 mediate
sphingosine-1-phoshate; S1PR1, S1P receptor 1; SEM, standard error of the meFigure S16). These results indicate that approaches
aimed at elevating muscle S1P may be beneficial to
promote muscle regeneration in additional muscle
wasting diseases.
Longer-term treatment with THI shows a functional
benefit in uninjured mdx muscle
To this point we have largely examined the role of S1P
in promoting muscle regeneration in acutely injured dys-
trophic muscles. Since long-term intramuscular injec-
tions of S1P are neither feasible nor practical (the
injections also cause damage), we decided to revisit the
use of THI for elevating S1P muscle content. Although
our initial experiments with THI showed little benefit in
uninjured mdx muscles, they were short-term and in
older animals with severe pathology (Figures 2, 3), or
adult animals (Figure 4) at a point when hypertrophy
and robust regeneration compensate for degeneration in
limb muscles [24,68,69]. Therefore, we examined longer-
term treatment of THI in younger mdx mice at 4 weeks
of age, a time point characterized by significant muscle
degeneration prior to the compensatory period [70]. For
this experiment, uninjured mdx4cv animals were treated
for 1 month, beginning at 4 weeks of age, with THI or
vehicle in the drinking water (Figure 8A) [11]. At 8 weeks
of age, we assessed the functional benefit of THI treat-
ment by analyzing EDL specific force via myography. Ininjured mdx EDL muscles. (A) Experimental schematic outlining the
ere treated for 4 weeks ad libitum with 50 mg/l THI (n = 4) or vehicle
nificant increase in maximal specific force with THI treatment. *P <0.05
act to not only promote myogenic cell activation and muscle repair,
d signaling. EDL, extensor digitorum longus; MO, month-old; S1P,
an; THI, 2-acetyl-4(5)-tetrahydroxybutyl imidazole.
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greater specific force compared to vehicle-treated controls
(Figure 8B). This data demonstrates that elevating S1P
levels is beneficial for the chronic muscle injury that
occurs early in muscular dystrophy.
Discussion
We have shown that systemic administration of the
pharmacological agent THI by IP injection to dystrophic
mdx mice led to elevated levels of S1P in recovering in-
jured muscle tissue, as well as a reduction of fibrosis and
fat infiltration, both pathological indicators of muscle
wasting (Figure 2). Additionally, systemic THI led to a
significant increase in muscle fiber size and specific force
of CTX-injured muscles (Figures 3 and 4). In turn,
ex vivo administration of high levels of S1P resulted in
specific force levels in uninjured mdx EDL muscles
(Figure 4D). To pursue a better understanding of how
elevated S1P reduces DMD pathology, we found that
direct administration of S1P via intramuscular injection
doubles muscle S1P content compared to the S1P levels
reached with IP injections of THI. In addition, intramus-
cular S1P injections led to an increase in myogenic cells
(Myf5+) and induced phosphorylation of S1PR1, which
was particularly abundant in newly regenerating fibers
(Figure 7, Additional file 1: Figure S15), as well as a sig-
nificant increase in rpS6 and P-rpS6 levels (Figure 6).
These results suggest that S1P not only works to activate
myogenic precursors but also elevates protein synthesis
in muscle fibers, potentially through S1PR1 mediated
signaling (summarized in Figure 8C). In summary, THI/
S1P administration led to improved regeneration and
pathology, higher muscle specific force, an increase in
the number of myogenic cells, and larger muscle fibers.
Our results indicate that S1P mediates satellite cell-
dependent and muscle fiber-dependent effects on skel-
etal muscle. If amelioration of muscle wasting occurs
through receptor-mediated signaling then S1P, elevated
intracellularly via THI, must be exported to activate the
S1P receptors. THI has been reported to inhibit the S1P
lyase, an enzyme whose active site is on the cytoplasmic
side of the endoplasmic reticulum. Therefore elevations
of S1P levels mediated via THI inhibition of the S1P
lyase presumably occur within the cytoplasm [71]. S1P
may also act intracellularly before possible export to
promote muscle wasting suppression. This alternative is
supported by our work with Drosophila, which have no
known S1P receptors [9], as well as by a recent report
that showed S1P interacts directly, intracellularly, with
histone deacetylases (HDACs) [72]. As HDAC inhibitors
have been previously shown to suppress dystrophic phe-
notypes in mdx mice, the actions of S1P on the sup-
pression of muscle wasting may occur in part through
such mechanisms [73]. It has also been reported thatreductions in HDAC activity result in an increase of
follistatin, an inhibitor of myostatin, which may explain
the amelioration of DMD pathology [74]. Our data sup-
port this possibility and suggest that the molecular
mechanism for the suppression of muscle degeneration
involves the anabolic pathways for muscle formation
rpS6. These components have been shown to lie down-
stream of myostatin and insulin-like growth factor [75].
Conclusion
Based on the work reported here, elevation of S1P may
be a fruitful strategy for ameliorating the pathology
manifested in patients afflicted with DMD and possibly
other muscle wasting diseases (for example dysferli-
nopathy). Therapies based on promoting S1P levels in
dystrophic muscle have the potential to improve path-
ology by promoting satellite cell and anabolic-mediated
regeneration. An obvious candidate for a small molecule
therapeutic is THI. Our work has shown that short-
term treatment of THI has significant efficacy in
increasing regenerative capacity in the mdx mouse fol-
lowing acute muscle injury, while longer treatment can
improve muscle function in younger uninjured mdx
muscle. Moreover, significant increases in muscle fiber
size have been suggested as a viable approach in
overcoming dystrophic muscle damage by promoting
strength and function [76]. Additionally, there are other
THI derivatives with increased oral bioavailability that
may be more effective at increasing and maintaining
high intramuscular S1P levels in long-term treatments,
which was necessary for functional improvement of un-
injured EDL muscles [10]. Alternatively there are inhi-
bitors of lipid phosphate phosphatases and/or S1P
phosphatases that may also increase intramuscular S1P
levels [10,77]. In addition, there are specific S1P recep-
tor agonists (for example FTY720) that are currently
FDA approved or in clinical trials [78,79]. Based on our
present results and those of others, future studies fo-
cused on S1P-based therapeutics for the treatment of
DMD and related myopathies are warranted.
Additional file
Additional file 1: Figure S1. Treatment with THI lowers mdx plasma
platelet levels. Figure S2. THI alters the expression of S1P regulatory
gene in mdx muscle. Figure S3. THI does not alter S1P plasma levels but
lowers plasma CK activity. Figure S4. Muscle weight is preserved and
hydroxy proline is reduced in injured muscles from THI treated mdx mice.
Figure S5. Fibrosis is lower in uninjured mdx TA muscles with THI
treatment. Figure S6. The number of centrally nucleated muscle fibers
does not change with THI. Figure S7. Diaphragm muscle fibers size
increases with THI treatment. Figure S8. THI treated mdx mice have an
elevated number of Pax7+ satellite cells. Figure S9. The microvasculature
of mdx muscles did not increase with THI. Figure S10. CTX injected in
the TA reaches and also damages the EDL. Figure S11. THI treatment
did not reduce T-cells in mdx diaphragms. Figure S12. Montages
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treated mdx4CV:Myf5nlacZ/+ animals, were created by combining
individual 10x photos. Figure S13. (A) Quantification of centrally
nucleated muscle fibers from the same injured TAs presented in Figure 5,
coincides with the number of newly regenerated fibers (eMyHC+ fibers)
observed in S1P injected TA muscles. (B) Quantification of the minimum
diameter of the largest eMyHC+ myofibers represented in Figure 5,
indicates a significant increase in regenerated fiber size with S1P
treatment. Figure S14. The expression of S1P receptors is reduced in
mdx muscle cells. Figure S15. Direct S1P administration results in
elevated levels of phosphorylation S1PR1 in mdx muscles. Figure S16.
S1P promotes muscle regeneration in the A/J mouse model of
dysferlinopathy. Table S1. Average number of Evans Blue+ muscle fibers
within each muscle group.
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